

## References

**AbdAlla S, Lothar H, El Massiery A et al.** Increased AT (1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. *Nat Med* 2001; 7: 1003–1009.

**Abdella TN, Anderson GD, Hays JM et al.** Relationship of hypertensive disease to abruptio placentae. *Obstet. Gynecol.* 1984; 63: 365-370.

**ACOG Committee on Obstetric Practice.** ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. No. 33, January 2002. *Obstet. Gynecol.* 2002; 99:159–167.

**Anderson CM and Ren J.** Leptin, leptin resistance and endothelial dysfunction in pre-eclampsia. *Cell Mol Biol (Noisy-le-grand.* 2002; 48 Online Pub: OL323-9).

**Arnholdt H, Meisel F, Fandrey K, et al.** Proliferation of villous trophoblast of the human placenta in normal and abnormal pregnancies. *Virchows Arch B Cell Pathol Incl Mol Pathol* 1991; 60:365-372.

**Artico LG, Madi JM, Godoy AE et al.** Histopathological changes in human placentas related to hypertensive disorders. *Rev Bras Ginecol Obstet.* 2009; 31(1):10-16.

**Badria LF, Abu-Heija A, Zayed F, et al.** Has consanguinity any impact on occurrence of pre-eclampsia and eclampsia? *J Obstet Gynaecol* 2001; 21: 358–360.

**Baergen RN.** Placental Malperfusion, In : BaergenRN (ed) Manual of Benirschke and Kaufmann's Pathology of the Human Placenta, New York, Springer Science+Business Media, Inc.,2005:332-350.

**Barbara NP, Wrana JL and Letarte M.** Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor- $\beta$  superfamily. *J Biol Chem.* 1999; 274:584–594.

**Bartha JL, Romero-Carmona R, Escobar-Llompert M, et al.** The relationships between leptin and inflammatory cytokines in women with pre-eclampsia. *Br J Obstet Gynaecol* 2001; 108:1272–1276.

**Bellón T, Corbí A, Lastres P, et al.** Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. *Eur J Immunol.* 1993; 23(9):2340-2345.

**Benirschke K , Kaufmann P and Baergen RN.** Maternal Diseases Complicating Pregnancy: Diabetes, Tumors, Preeclampsia, Lupus Anticoagulant, In : Benirschke K , KaufmannP ,and Baergen RN(eds) Pathology of the human placenta , 5<sup>th</sup> edition , New York, Springer Science+Business Media, Inc.,2006:584-656.

**Benirschke K and Kaufmann P.** Architecture of normal villous tree. In: Benirschke K, KaufmannP (eds) Pathology of the human placenta. 4<sup>th</sup> edition, New York: Springer-Verlag,2000: 116-154.

**Berends AL, de Groot CJ, Sijbrands EJ, et al.** Shared constitutional risks for maternal vascular-related pregnancy complications and future cardiovascular disease. *Hypertension* 2008; 51: 1034–1041.

**Bergh PA and Navot D.**the impact of embryonic development and endometrial maturity on the timing of implantation. *Fertil Steril* 1992; 58:537-542.

**Bertolino P, Deckers M, Lebrin F, et al.** Transforming growth factor-B signal transduction in angiogenesis and vascular disorders. *Chest* 2005; 128:585S-90S.

**Blackburn ST** . Prenatal period and placental physiology, In: Blackburn ST (ed) *Maternal, fetal, & neonatal physiology*, Missouri, Elsevier Health Sciences, 2007:70-124.

**Borowski K, Kair L, Zeng S, et al.** Lack of association of FAS gene and preeclampsia. Abstract No 706. Presented at the 29<sup>th</sup> Annual Meeting of the Society for Maternal-Fetal Medicine,2009: 26–31.

**Boyd JD and Hamilton WJ.**The Human Placenta. In: Boyd JD and Hamilton WJ (eds) *placenta*, Cambridge, Heffer & Sons Ltd, 1970:57-115.

**Burton GJ, Skepper JN, Hempstock J, et al.** A reappraisal of the contrasting morphological appearances of villous cytotrophoblast cells during early human pregnancy; evidence for both apoptosis and primary necrosis. *Placenta* 2003; 24:297–305.

**Caniggia I, Grisar-Graunosky S, Kuliszewsky M, et al.** Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. *J Clin Invest* 1999; 103: 1641–1650.

**Caniggia I, Taylor CV, Ritchie JW, et al.** Endoglin regulates trophoblast differentiation along the invasive pathway in human placental villous explants. *Endocrinology* 1997; 138:4977-88.

**Carmeliet P, Moons L, Luttun A, et al.** Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. *Nat Med* 2001; 7: 575–583.

**Carr DB, Epplein M, Johnson CO, et al.** A sister's risk: family history as a predictor of preeclampsia. *Am J Obstet Gynecol* 2005; 193: 965-972.

**Carson DD.** The glycobiology of implantation. *Front Biosci* 2002; 7(d) 1535-1544.

**Castellucci M, Kosanke G, Verdenelli F, et al.** Villous sprouting: fundamental mechanisms of human placental development. *Hum Reprod Update* 2000; 6:485–94.

**Cervar M, Blaschitz A, Dohr G, et al.** Paracrine regulation of distinct trophoblast functions in vitro by placental macrophages. *Cell Tissue Res* 1999; 295:297-305.

**Chedraui P, Lockwood CJ, Schatz F et al.** Increased plasma soluble fms-like tyrosine kinase 1 and endoglin levels in pregnancies complicated with preeclampsia. *J Matern Fetal Neonatal Med.* 2009; 22(7):565-70.

**Cheifetz S, Bellon T, Cales C, et al.** Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. *J Biol Chem.* 1992; 267:19027–19030.

**Clark DE, Smith SK, He Y, et al.** A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. *Biol Reprod* 1998; 59: 1540–1548.

**Crawford J.** A study of human placental growth with observations on the placenta in erythroblastosis foetalis. *Br J Obstet Gynaecol* 1959; 66:855.

**Cunningham FG, Leveno KJ, Bloom SL, et al.** Implantation, Embryogenesis, and Placental Development: Introduction, In Cunningham FG, Leveno KJ, Bloom SL, et al. (eds) *Williams Obstetrics*, 23<sup>rd</sup> Edition, McGraw-Hill Companies, Inc., 2010:39-90.

**Dearden L and Ockleford CD.** Structure of human trophoblast: correlation with function. In: Loke YW, Whyte A (eds). *Biology of trophoblast*. Amsterdam, Elsevier, 1983: 69–110.

**Demir R, Kosanke G, Kohnen G, et al.** Classification of human placental stem villi: review of structural and functional aspects. *Microsc Res Tech* 1997; 38:29–41.

**Dildy GA and Belfort MA .** Complications of pre-eclampsia, In Lyall F, and Belfort M (eds) *Pre-eclampsia Etiology and Clinical Practice*, Cambridge, Cambridge University Press, 2007:406-423.

**Duckitt K and Harrington D.** Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. *BMJ* 2005; 330-565.

**Duff SE, Li C, Garland JM, et al.** CD105 is important for angiogenesis: evidence and potential applications. *FASEB J* 2003; 17:984-92.

**Dvorak H F, Nagy JA, Feng et al.** Current Topics in Microbiology and Immunology, In: Claesson-Welsh L (Ed.), *Vascular growth factors and angiogenesis*, Springer-Verlag Berlin Heidelberg, Germany, 1999:97-132.

**Ebos JM, Bocci G, Man S, et al.** A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. *Mol Cancer Res* 2004; 2: 315–326.

**England LJ, Levine RJ, Qian C, et al.** Smoking before pregnancy and risk of gestational hypertension and preeclampsia. *Am J Obstet Gynecol* 2002; 186: 1035–1040.

**Esplin MS, Fausett MB, Fraser A, et al.** Paternal and maternal components of the predisposition to preeclampsia. *N Engl J Med* 2001; 344: 867–872.

**Feinberg RF, Kliman HJ, and Lockwood CJ.** Is oncofetal fibronectin a trophoblast glue for human implantation? *Am J Pathol* 1991; 138:537-543.

**Feneley MR and Burton GJ.** Villous composition and membrane thickness in the human placenta at term: a stereological study using unbiased estimators and optimal fixation techniques. *Placenta* 1991; 12:131–142.

**Ferrazzani S, DeCarolis S, Pomini F, et al.** The duration of hypertension in the puerperium of preeclamptic women: relationship with renal impairment and week of delivery. *Am J Obstet Gynecol* 1994; 171:506–512.

**Fisher KA, Luger A, Spargo BH, et al.** Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. *Medicine (Baltimore)* 1981; 60: 267–276.

**Fitzgerald JS, Poehlmann TG, Schleussner E, et al:** Trophoblast invasion: the role of intracellular cytokine signaling via signal transducer and activator of transcription 3 (STAT3). *Hum Reprod Update* 2008; 14(4):335-344.

**Fonsatti E, Altomonte M, Nicotra MR, et al.** Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenic blood vessels. *Oncogene* 2003; 22:6557-63.

**Fox H.** The significance of placental infarction in perinatal morbidity and mortality. *Biologica Neonatorum* 1967 (b); 11: 87 - 105.

**Fu ML, Herlitz H, Schulze W, et al.** Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. *J Hypertens* 2000; 18: 945–953.

**Gifford RW, August PA, Cunningham G, et al.** Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. *Am J Obstet Gynecol* 2000; 183:S1–S22.

**Gougos A and Letarte M.** "Identification of a Human Endothelial Cell Antigen with Monoclonal Antibody 44G4 Produced Against a Pre-B Leukemic Cell Line," *The Journal of Immunology* 1988; 141:1925-1933.

**Graf R, Matejevic D, Schuppan D, et al.** Molecular anatomy of the perivascular sheath in human placental stem villi: the contractile apparatus and its association to the extracellular matrix. *Cell Tissue Res* 1997; 290:601–7.

**Hamilton W and Boyd J:** Trophoblast in human utero-placental arteries. *Nature* 1966; 212:906-908.

**Hanna J, Goldman-Wohl D, Hamani Y, et al.** Decidual NK cells regulate key developmental processes at the human fetal/maternal interface. *Nat Med* 2006; 12: 1065–1074.

**Hertig AT.** The placenta: Some new knowledge about an old organ. *Obstet. Gynecol.* 1962; 20:859-566.

**Hladunewich M, Karumanchi SA and Lafayette R.** Pathophysiology of the Clinical Manifestations of Preeclampsia. *Clin J Am Soc Nephrol* 2007; 2: 543-549.

**Huppertz B, Frank HG and Kaufmann P.** The apoptosis cascade—morphological and immunohistochemical methods for its visualization. *Anat Embryol* 1999; 200:1–18.

**Huppertz B.** The anatomy of the normal placenta. *J Clin Pathol* 2008; 61: 1296-1302.

**Johansen M, Redman CW, Wilkins T, et al.** Trophoblast deportation in human pregnancy—its relevance for pre-eclampsia. *Placenta* 1999; 20:531–9.

**Kanasaki K, Palmsten K, Sugimoto H, et al.** Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. *Nature* 2008; 453: 1117–1121.

**Karumanchi SA and Epstein FH.** Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia? *Kidney Int* 2007; 71: 959–961.

**Karumanchi SA and Lindheimer MD.** Preeclampsia pathogenesis: “triple a rating”-autoantibodies and antiangiogenic factors. *Hypertension* 2008; 51: 991–992.

**Kaufmann P and Huppertz B .** Tenney\_Parker changes and apoptotic versus necrotic shedding of trophoblast in normal pregnancy and pre-



eclampsia, In Lyall F, and Belfort M (eds) Pre-eclampsia Etiology and Clinical Practice, Cambridge, Cambridge University Press,2007:152-163.

**Kaufmann P and Kingdom J** . Development of the vascular system in the placenta. In: Risau W and Rubanyi G (eds) Morphogenesis of Endothelium, Amsterdam, Harwood,2000: 255-275.

**Kaufmann P, Black S, and Huppertz B**. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003; 69:1–7.

**Kaufmann P, Nagl W and Fuhrmann B**. Die funktionelle Bedeutung der Langhanszellen der menschlichen Placenta. Anat Anz 1983; 77:435–6.

**Kaufmann P, Sen DK and Schweikhart G**. Classification of human placental villi. 1. Histology. Cell Tissue Res 1979; 200:409–23.

**Kaufmann P**. Development and differentiation of the human placental villous tree. Biblthca Anat 1982; 22:29–39.

**Kendall RL and Thomas KA**. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993;90: 10705–10709.

**Khan F, Belch JJ, MacLeod M, et al**. Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops. Hypertension 2005; 46: 1123–1128.

**Khong TY, De Wolf F, Robertson WB et al**. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93:1049-59.

**Khong TY, Pearce JM and Robertson WB.** Acute atherosclerosis in preeclampsia: maternal determinants and fetal outcome in the presence of the lesion. *Am J Obstet Gynecol* 1987; 157:360–363.

**Kim NY, Lee DS, Jeong DH et al.** The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. *Prenat Diagn* 2009; 29: 464–470.

**Kishwara S, Ara S, Abu Rayhan K et al.** Morphological Changes of Placenta in Preeclampsia. *Bangladesh Journal of Anatomy* 2009; 7(1):49-54.

**Klonoff-Cohen HS, Savitz DA, et al.** An epidemiologic study of contraception and preeclampsia. *JAMA* 1989; 262: 3143–3147.

**Kos M, Czernobilsky B, Hlupic L, et al.** Pathological Changes in Placentas from Pregnancies with Preeclampsia and Eclampsia with Emphasis on Persistence of Endovascular Trophoblastic Plugs. *Croat Med J* 2005; 46(3):404-409.

**Kosanke G, Kadyrov M, Korr H, et al.** Maternal anemia results in increased proliferation in human placental villi. *Trophoblast Res* 1998; 11:339–57.

**Lachmeijer AMA, Crusius JBA, Pals G, et al.** Polymorphisms in the tumor necrosis factor and lymphotoxin- $\alpha$  gene region and preeclampsia. *Obstet. Gynecol.* 2001; 98:612.

**Lafayette RA, Druzin M, Sibley R, et al.** Nature of glomerular dysfunction in pre-eclampsia. *Kidney Int* 1998; 54: 1240–1249.

**Laivuori H.** Genetic aspects of preeclampsia. *Front Biosci* 2007; 12:2372–82.

**Lam C, Lim KH and Karumanchi SA.** Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. *Hypertension* 2005; 46: 1077–1085.

**Lebrin F, Deckers M, Bertolino P et al.** TGF- $\beta$  receptor function in the endothelium. *Cardiovasc Res* 2005; 65:599-608.

**Lessey BA and Castelbaum AJ:** Integrins and implantation in the human. *Rev Endocr Metab Disord* 2002;3:107-117.

**Lessey BA, Castelbaum AJ, Sawin SW, et al.** Integrins as markers of uterine receptivity in women with primary unexplained infertility. *Fertil Steril* 1995; 63:535.

**Lessey BA, Ilesanmi AO, Lessey MA, et al.** Luminal and glandular endometrial epithelium express integrins differentially throughout the menstrual cycle: Implications for implantation, contraception, and infertility. *Am J Reprod Immunol* 1996;35:195-204.

**Levine RJ, Lam C, Qian C, et al.** Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. *N Engl J Med* 2006; 355: 992–1005.

**Levine RJ, Maynard SE, Qian C, et al.** Circulating angiogenic factors and the risk of preeclampsia. *N Engl J Med* 2004; 350: 672-83.

**Licht P, Russu V and Wildt L.** On the role of human chorionic gonadotropin (hCG) in the embryo-endometrial microenvironment: Implications for differentiation and implantation. *Semin Reprod Med* 2001; 19:37-47.

**Lim JH, Kim SY, Park SY, et al.** Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. *Obstet. Gynecol.* 2008; 111:1403-1409.

**Lim KH, Friedman SA, Ecker JL, et al.** The clinical utility of serum uric acid measurements in hypertensive diseases of pregnancy. *Am J Obstet Gynecol* 1998; 178:1067–71.

**Lindhard A, Bentin-Ley U, Ravn V, et al.** Biochemical evaluation of endometrial function at the time of implantation. *Fertil Steril* 2002; 78:221-233.

**Livingston JC, Park V, Barton JR, et al.** Lack of association of severe preeclampsia with maternal and fetal mutant alleles for tumor necrosis factor alpha and lymphotoxin alpha genes and plasma tumor necrosis levels. *Am J Obstet Gynecol* 2001;184:1273-1277.

**Loke YM and King A .** Human trophoblast development. In: Loke YM and King A (eds) *Human Implantation: Cell Biology and Immunology.* Cambridge, Cambridge University Press, 1995:32-62.

**Luttun A, Tjwa M, Moons L, et al.** Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. *Nat Med* 2002;8: 831–840.

**Macara L, Kingdom JC, Kaufmann P, et al.** Structural analysis of placental terminal villi from growth-restricted pregnancies with abnormal umbilical artery Doppler waveforms. *Placenta* 1996; 17:37-48.

**Mackay AP, Berg CJ, and Atrash HK.** Pregnancy-related mortality from preeclampsia and eclampsia. *Obstet. Gynecol.* 2001; 97:533–8.

**Maharaj AS, Walshe TE, Saint-Geniez M, et al.** VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. *J Exp Med* 2008; 205: 491–501.

**Majumdar S, Dasgupta H, Bhattacharya K et., al.** A Study of Placenta in Normal and Hypertensive Pregnancies. *J. Anat. Soc. India* 2005; 54 (2): 1-9.

**Makris A, Thornton C, Thompson J, et al.** Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. *Kidney Int* 2007; 71: 977–984.

**Manaster I, Mizrahi S, Goldman-Wohl D, et al.** Endometrial NK cells are special immature cells that await pregnancy. *J Immunol* 2008; 181:1869-1876.

**Matsuo K, Kooshesh S, Dinc M, Sun et al.** Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. *Am J Perinatol* 2007; 24: 257–266.

**Mayhew TM, Leach L, McGee R, et al.** Proliferation, differentiation and apoptosis in villous trophoblast at 13–41 weeks of gestation (including observations on annulate lamellae and nuclear pore complexes. *Placenta* 1999; 20:407–22.

**Maynard SE, Min JY, Merchan J, et al.** Excess placental soluble Fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest* 2003; 111(5):649-58.

**Meekins JW, Pijnenborg R, Hanssens M, et al.** A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. *Br J Obstet Gynaecol* 1994; 101: 669–674.

**Moldenhauer JS, Stanek J, Warshak C, et al.** The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. *Am J Obstet Gynecol* 2003; 189:1173–1177.

**Moore JJ, Dubyak GR, Moore RM, et al.** Oxytocin activates the inositol-phospholipid-protein kinase-C system and stimulates prostaglandin production in human amnion cells. *Endocrinology* 1988; 123:1771-1777.

**Nagamatsu T, Fujii T, Kusumi M, et al.** Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. *Endocrinology* 2004; 145: 4838–48454.

**Navot D and Bergh P:** Preparation of the human endometrium for implantation. *Ann N Y Acad Sci* 1991; 622:212-219.

**Nelson DM.** Apoptotic changes occur in syncytiotrophoblast of human placental villi where fibrin type fibrinoid is deposited at discontinuities in the villous trophoblast. *Placenta* 1996; 17:387–91.

**Nilsson E, Ros HS, Cnattingius S, et al.** The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: A family study. *Br J Obstet Gynaecol* 2004; 111:200--206.

**Ockleford CD and Wakely J .** The skeleton of the placenta. In: Harrison RJ, Holmes RL (eds) *Progress in anatomy*. London, Cambridge University Press, 1981:19–48.

**O'Sullivan CM, Liu SY, Karpinka JB, et al.** Embryonic hatching enzyme strypsin/ISP1 is expressed with ISP2 in endometrial glands during implantation. *Mol Reprod Dev* 2002; 62:328-334.

**Palmer SK, Moore LG, Young D, et al.** Altered blood pressure course during normal pregnancy and increased preeclampsia at high altitude (3100 meters) in Colorado. *Am J Obstet Gynecol* 1999; 180: 1161–1168.

**Pijnenborg R, Bland JM, Robertson WB, et al.** The pattern of interstitial trophoblastic invasion of the myometrium in early human pregnancy. *Placenta*. 1981; 2:303-16.

**Pijnenborg R, Bland JM, Robertson WB, et al.** Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy. *Placenta*. 1983; 4:397-413.

**Pijnenborg R.** Trophoblast invasion. *Reprod Med Rev* 1994; 3:53-73.

**Podjarny E, Losonczy G and Baylis C.** Animal models of preeclampsia. *Semin Nephrol* 2004; 24(6):596-606.

**Prakobphol A, Genbacev O, Gormley M, et al.** A role for the L-selectin adhesion system in mediating cytotrophoblast emigration from the placenta. *Dev Biol* 2006;298:107-117.

**Pretorius DH, Chau C, Poeltler DM, et al.** Placental cord insertion, visualisation with prenatal ultrasonography. *J Ultrasound Med* 1996; 15: 585 – 593.

**Rajakumar A, Brandon HM, Daftary A, et al.** Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. *Placenta* 2004; 25: 763–769.

**Ramsey EM and Donner MW** . Placental Vasculature and Circulation: anatomy, physiology, radiology, clinical aspects : atlas and textbook. In: Ramsey EM and Donner MW (eds) Anatomy . Thieme, Stuttgart ,1980:1-52.

**Reddy A, Suri S, Sargent IL, et al.** Maternal Circulating Levels of Activin A, Inhibin A, sFlt-1 and Endoglin at Parturition in Normal Pregnancy and Pre-Eclampsia. PLoS ONE 2009;4(2): e4453. doi:10.1371/journal.pone.0004453

**Redman CW and Sargent IL.** Latest advances in understanding preeclampsia. Science 2005; 308: 1592–1594.

**Roberts JM, Taylor RN, Musci TJ, et al.** Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200–1204.

**Roberts JM.** Objective evidence of endothelial dysfunction in preeclampsia. Am J Kidney Dis 1999; 33: 992–997.

**Robinson CJ and Johnson DA.** Soluble endoglin as a second-trimester marker for Preeclampsia. Am J Obstet Gynecol 2007; 197:174.

**Sandrim VC, Palei AC, Metzger IF, et al.** Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble Fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension 2008; 52(2):402-407.

**Sargent IL, Germain SJ, Sacks GP, et al.** Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol 2003; 59: 153–160.



**Saudan P, Brown MA, Buddle ML, et al.** Does gestational hypertension become preeclampsia? *Br J Obstet Gynaecol* 1998; 105:1177–84.

**Schmidt MJ, Cook L and Zhang P.** Maternal vasculopathy and diagnosis of pre-eclampsia: Histologic analyses of placentas. *Modern Pathol.* 2005; 18 Suppl. 1: p. 306A, abstract 1416.

**Schwartz RB, Feske SK, Polak JF, et al.** Preeclampsia-eclampsia: clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. *Radiology* 2000; 217: 371–376.

**Sela S, Itin A, Natanson-Yaron S, et al.** A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. *Circ Res* 2008; 102: 1566–1574.

**Shah RK, Jagiwala KS and Vyas PK.** Placental morphology and fetal growth in normal and abnormal pregnancies. *J Obstet. Gynecol. India* 1985; 35: 1089-94.

**Sharma JB, Kumar A, Kumar A, et al.** Effect of lycopene on preeclampsia and intra-uterine growth retardation in primigravidas. *Int J Gynaecol Obstet* 2003;81: 257–262.

**Shembrey MA and Noble AD.** An instructive case of abdominal pregnancy. *Aust NZ J Obstet Gynaecol* 1995; 35: 220–221.

**Sibai BM.** Chronic hypertension in pregnancy. *Obstet. Gynecol.* 2002; 100:369–77.

**Sibai BM.** Diagnosis and management of gestational hypertension and preeclampsia. *Obstet. Gynecol.* 2003; 102:181–92.

**Sibai BM.** Diagnosis, prevention, and management of eclampsia. *Obstet. Gynecol.* 2005; 105: 402–410.

**Sikkema JM, van Rijn BB, Franx A, et al.** Placental superoxide is increased in pre-eclampsia. *Placenta* 2001; 22: 304–308.

**Skjaerven R, Wilcox AJ and Lie RT.** The interval between pregnancies and the risk of preeclampsia. *N Engl J Med* 2002; 346: 33–38.

**Staff AC, Braekke K, Johnsen GM et al.** Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. *Am J Obstet Gynecol* 2007; 197(2):176.e1-6.

**Steinberg G, Khankinb EV and Karumanchi SA.** Angiogenic factors and preeclampsia. *Thrombosis Research* 2009; 123 Suppl. 2, S93–S99.

**Streeter GL.** A human embryo (Mateer) of the presomite period. *Contrib Embryol* 1920; 9:389.

**Strevens H, Wide-Swensson D, Hansen A, et al.** Glomerular endotheliosis in normal pregnancy and pre-eclampsia. *Br J Obstet Gynaecol* 2003; 110: 831–836.

**Todros T, Sciarrone A, Piccoli E., et al.** Umbilical Doppler waveforms and placental villous angiogenesis in pregnancies complicated by fetal growth restriction. *Obstet. Gynecol.* 1999; 93:499-503.

**Tsiaras A and Werth B.** Photomicrograph of an early implanted blastocyst. In: **Tsiaras A and Werth B (eds)** *From Conception to Birth*. New York, Doubleday, 2002:175-189.

**Tubbergen P, Lachmeijer AM, Althuisius SM, et al.** Change in paternity: a risk factor for preeclampsia in multiparous women? *J Reprod Immunol* 1999;45: 81–88.

**Tuffnell DJ, Jankowicz D, Lindow SW, et al.** Outcomes of severe pre-eclampsia/eclampsia in Yorkshire 1999/2003. *Br J Obstet Gynaecol* 2005; 112: 875–880.

**Udainia A and Jain ML.** Morphological Study of Placenta in Pregnancy Induced Hypertension with its Clinical Relevance. *J. Anat. Soc. India* 2001; 50(1) 24-27.

**Udainia A, Bhagwat SS and Mehta CD.** Relation between placental surface area, infarction and foetal distress in pregnancy induced hypertension with its clinical relevance. *J. Anat. Soc. India* 2004, 53; 1: 27-30.

**Venkatesha S, Toporsian M, Lam C, et al.** Soluble endoglin contributes to the pathogenesis of preeclampsia. *Nat Med* 2006; 12: 642–649.

**Wagner LK.** Diagnosis and management of preeclampsia. *American Family Physician.* 2004; 70: 2317-2324.

**Wallukat G, Homuth V, Fischer T, et al.** Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. *J Clin Invest* 1999; 103: 945–952.

**Walsh SW, Vaughan JE, Wang Y, et al.** Placental isoprostane is significantly increased in preeclampsia. *FASEB J* 2000; 14: 1289–1296.

**Wang A, Rana S and Karumanchi SA.** Preeclampsia: The Role of Angiogenic Factors in Its Pathogenesis. *Physiology* 2009; 24:147-158.

**Ward K and Lindheimer MD.** Genetic factors in the etiology of preeclampsia/eclampsia. In : Lindheimer MD, Roberts JM, Cunningham FG (eds) Chesley's Hypertensive Disorders in Pregnancy, 3<sup>rd</sup> edititon , London , Elsevier, 2009:51-71.

**Witlin AG and Sibai BM.** Magnesium sulfate therapy in preeclampsia and eclampsia. *Obstet. Gynecol.* 1998; 92:883–9.

**Xia Y, Wen H, Bobst S, et al.** Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. *J Soc Gynecol Investig* 2003; 10: 82–93.

**Yallampalli C and Garfield RE.** Inhibition of nitric oxide synthesis in rats during pregnancy produces signs similar to those of preeclampsia. *Am J Obstet Gynecol* 1993; 169: 1316–1320.

**Zhou CC, Zhang Y, Irani RA, et al.,** Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. *Nat Med* 2008;14: 855–862.

**Zhou Y, Damsky CH and Fisher SJ.** Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? *J Clin Invest* 1997; 99: 2152–2164. **B**

**Zhou Y, Fisher SJ, Janatpour M, et al.** Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? *J Clin Invest* 1997; 99: 2139–2151. **A**

**Zhou Y, McMaster M, Woo K, et al.,** Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are

---

---

## References

dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. *Am J Pathol* 2002; 160: 1405–1423.

**Zusterzeel PL, Peters WH, De Bruyn MA, et al.** Glutathione Stransferase isoenzymes in decidua and placenta of preeclamptic pregnancies. *Obstet. Gynecol.* 1999; 94: 1033–1038.